Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

Abstract

This trial did not demonstrate benefit of adding low-dose oral methotrexate or every other month IV methylprednisolone to interferon beta-1a in relapsing-remitting multiple sclerosis.